Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group

Yasuyoshi Morita; Akihisa Kanamaru; Yasushi Miyazaki; Daisuke Imanishi; Fumiharu Yagasaki; Mitsune Tanimoto; Kazutaka Kuriyama; Toru Kobayashi; Shion Imoto; Kazunori Ohnishi; Tomoki Naoe; Ryuzo Ohno

doi:10.1007/s12185-009-0473-4

Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group

Yasuyoshi Morita, Akihisa Kanamaru, Yasushi Miyazaki, Daisuke Imanishi, Fumiharu Yagasaki, Mitsune Tanimoto, Kazutaka Kuriyama, Toru Kobayashi, Shion Imoto, Kazunori Ohnishi, Tomoki Naoe, Ryuzo Ohno

Research output: Contribution to journal › Article › peer-review

15 Citations (Scopus)

Abstract

A total of 120 patients with high-risk myelodysplastic syndrome (MDS) and AML progressed from MDS (MDS-AML) were registered in a randomized controlled study of the Japan Adult Leukemia Study Group (JALSG). Untreated adult patients with high-risk MDS and MDS-AML were randomly assigned to receive either idarubicin and cytosine arabinoside (IDR/Ara-C) (Group A) or low-dose cytosine arabinoside and aclarubicin (CA) (Group B). The remission rates were 64.7% for Group A (33 of 51 evaluable cases) and 43.9% for Group B (29 out of 66 evaluable cases). The 2-year overall survival rates and disease-free survival rates were 28.1 and 26.0% for Group A, and 32.1 and 24.8% for Group B, respectively. The duration of CR was 320.6 days for Group A and 378.7 days for Group B. There were 15 patients who lived longer than 1,000 days after diagnosis: 6 and 9 patients in Groups A and B, respectively. However, among patients enrolled in this trial, intensive chemotherapy did not produce better survival than low-dose chemotherapy. In conclusion, it is necessary to introduce the first line therapy excluding the chemotherapy that can prolong survival in patients with high-risk MDS and MDS-AML.

Original language	English
Pages (from-to)	97-103
Number of pages	7
Journal	International journal of hematology
Volume	91
Issue number	1
DOIs	https://doi.org/10.1007/s12185-009-0473-4
Publication status	Published - Jan 2010
Externally published	Yes

Keywords

HSCT
Induction therapy
JALSG MDS200
MDS
MDS-AML

ASJC Scopus subject areas

Hematology

Access to Document

10.1007/s12185-009-0473-4

Cite this

Morita, Y., Kanamaru, A., Miyazaki, Y., Imanishi, D., Yagasaki, F., Tanimoto, M., Kuriyama, K., Kobayashi, T., Imoto, S., Ohnishi, K., Naoe, T., & Ohno, R. (2010). Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group. International journal of hematology, 91(1), 97-103. https://doi.org/10.1007/s12185-009-0473-4

Morita, Y, Kanamaru, A, Miyazaki, Y, Imanishi, D, Yagasaki, F, Tanimoto, M, Kuriyama, K, Kobayashi, T, Imoto, S, Ohnishi, K, Naoe, T & Ohno, R 2010, 'Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group', International journal of hematology, vol. 91, no. 1, pp. 97-103. https://doi.org/10.1007/s12185-009-0473-4

@article{e27e5f9335b843c4b657a3f42653ec9a,

title = "Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group",

abstract = "A total of 120 patients with high-risk myelodysplastic syndrome (MDS) and AML progressed from MDS (MDS-AML) were registered in a randomized controlled study of the Japan Adult Leukemia Study Group (JALSG). Untreated adult patients with high-risk MDS and MDS-AML were randomly assigned to receive either idarubicin and cytosine arabinoside (IDR/Ara-C) (Group A) or low-dose cytosine arabinoside and aclarubicin (CA) (Group B). The remission rates were 64.7% for Group A (33 of 51 evaluable cases) and 43.9% for Group B (29 out of 66 evaluable cases). The 2-year overall survival rates and disease-free survival rates were 28.1 and 26.0% for Group A, and 32.1 and 24.8% for Group B, respectively. The duration of CR was 320.6 days for Group A and 378.7 days for Group B. There were 15 patients who lived longer than 1,000 days after diagnosis: 6 and 9 patients in Groups A and B, respectively. However, among patients enrolled in this trial, intensive chemotherapy did not produce better survival than low-dose chemotherapy. In conclusion, it is necessary to introduce the first line therapy excluding the chemotherapy that can prolong survival in patients with high-risk MDS and MDS-AML.",

keywords = "HSCT, Induction therapy, JALSG MDS200, MDS, MDS-AML",

author = "Yasuyoshi Morita and Akihisa Kanamaru and Yasushi Miyazaki and Daisuke Imanishi and Fumiharu Yagasaki and Mitsune Tanimoto and Kazutaka Kuriyama and Toru Kobayashi and Shion Imoto and Kazunori Ohnishi and Tomoki Naoe and Ryuzo Ohno",

note = "Funding Information: Acknowledgments We would like to thank the participating physicians in the Japan Adult Leukemia Study Group (JALSG) MDS200 study for their cooperation. This work was supported in part by grants-in-aid for Scientific Research from the Japanese Ministry of Education, Culture, Sport, Science, and Technology, and grants-in-aid for Cancer Research from the Japanese Ministry of Health, Labor, and Welfare.",

year = "2010",

month = jan,

doi = "10.1007/s12185-009-0473-4",

language = "English",

volume = "91",

pages = "97--103",

journal = "International Journal of Hematology",

issn = "0925-5710",

publisher = "Springer Japan",

number = "1",

}

TY - JOUR

T1 - Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group

AU - Morita, Yasuyoshi

AU - Kanamaru, Akihisa

AU - Miyazaki, Yasushi

AU - Imanishi, Daisuke

AU - Yagasaki, Fumiharu

AU - Tanimoto, Mitsune

AU - Kuriyama, Kazutaka

AU - Kobayashi, Toru

AU - Imoto, Shion

AU - Ohnishi, Kazunori

AU - Naoe, Tomoki

AU - Ohno, Ryuzo

N1 - Funding Information: Acknowledgments We would like to thank the participating physicians in the Japan Adult Leukemia Study Group (JALSG) MDS200 study for their cooperation. This work was supported in part by grants-in-aid for Scientific Research from the Japanese Ministry of Education, Culture, Sport, Science, and Technology, and grants-in-aid for Cancer Research from the Japanese Ministry of Health, Labor, and Welfare.

PY - 2010/1

Y1 - 2010/1

N2 - A total of 120 patients with high-risk myelodysplastic syndrome (MDS) and AML progressed from MDS (MDS-AML) were registered in a randomized controlled study of the Japan Adult Leukemia Study Group (JALSG). Untreated adult patients with high-risk MDS and MDS-AML were randomly assigned to receive either idarubicin and cytosine arabinoside (IDR/Ara-C) (Group A) or low-dose cytosine arabinoside and aclarubicin (CA) (Group B). The remission rates were 64.7% for Group A (33 of 51 evaluable cases) and 43.9% for Group B (29 out of 66 evaluable cases). The 2-year overall survival rates and disease-free survival rates were 28.1 and 26.0% for Group A, and 32.1 and 24.8% for Group B, respectively. The duration of CR was 320.6 days for Group A and 378.7 days for Group B. There were 15 patients who lived longer than 1,000 days after diagnosis: 6 and 9 patients in Groups A and B, respectively. However, among patients enrolled in this trial, intensive chemotherapy did not produce better survival than low-dose chemotherapy. In conclusion, it is necessary to introduce the first line therapy excluding the chemotherapy that can prolong survival in patients with high-risk MDS and MDS-AML.

AB - A total of 120 patients with high-risk myelodysplastic syndrome (MDS) and AML progressed from MDS (MDS-AML) were registered in a randomized controlled study of the Japan Adult Leukemia Study Group (JALSG). Untreated adult patients with high-risk MDS and MDS-AML were randomly assigned to receive either idarubicin and cytosine arabinoside (IDR/Ara-C) (Group A) or low-dose cytosine arabinoside and aclarubicin (CA) (Group B). The remission rates were 64.7% for Group A (33 of 51 evaluable cases) and 43.9% for Group B (29 out of 66 evaluable cases). The 2-year overall survival rates and disease-free survival rates were 28.1 and 26.0% for Group A, and 32.1 and 24.8% for Group B, respectively. The duration of CR was 320.6 days for Group A and 378.7 days for Group B. There were 15 patients who lived longer than 1,000 days after diagnosis: 6 and 9 patients in Groups A and B, respectively. However, among patients enrolled in this trial, intensive chemotherapy did not produce better survival than low-dose chemotherapy. In conclusion, it is necessary to introduce the first line therapy excluding the chemotherapy that can prolong survival in patients with high-risk MDS and MDS-AML.

KW - HSCT

KW - Induction therapy

KW - JALSG MDS200

KW - MDS

KW - MDS-AML

UR - http://www.scopus.com/inward/record.url?scp=75049084540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75049084540&partnerID=8YFLogxK

U2 - 10.1007/s12185-009-0473-4

DO - 10.1007/s12185-009-0473-4

M3 - Article

C2 - 20047095

AN - SCOPUS:75049084540

SN - 0925-5710

VL - 91

SP - 97

EP - 103

JO - International Journal of Hematology

JF - International Journal of Hematology

IS - 1

ER -

Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this